This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Qudexy XR

Upsher-Smith Laboratories Inc.

Drug Names(s): topiramate extended release (ER), USL255

Description: USL255 is an extended-release formulation of topiramate. USL255 is designed to provide convenient once daily dosing and reduce fluctuations in topiramate blood levelsobserved with currently available topiramate options.

Topiramate (Topamax) is an anticonvulsant used to treat epilepsy in both children and adults. The mechanism of action of topiramate in obesity is unknown. It modulates effects at the gamma-aminobutyric acid (GABA-A) receptor and glutamate AMPA/kainate receptors, as well as producing state-dependent blockade of voltage-dependent Na+ or Ca2+ channels.


Qudexy XR News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug